Lesser Known Ankylosing Spondylitis Pharmacotherapy is an Untapped Market in the United States, Finds Frost & Sullivan

Lesser Known Ankylosing Spondylitis Pharmacotherapy is an Untapped Market in the United States, Finds Frost & Sullivan PR Newswire MOUNTAIN VIEW, California, Oct. 10, 2012 -- Additional therapeutic options are needed for patients who fail to respond to the current therapy MOUNTAIN VIEW, California, Oct. 10, 2012 /PRNewswire/ -- The treatment beyond standard of care for ankylosing spondylitis (AS) pharmacotherapeutics currently consists of a single drug class – tumor necrosis factor (TNF) inhibitors. This unavailability of alternative treatment represents an underserved and potentially significant market that is waiting for exploration. New analysis from Frost & Sullivan's (http://www.lifesciences.frost.com) United States Market for Ankylosing Spondylitis Pharmacotherapy research finds that the market earned revenues of more than $496.6 million in 2011 and estimates this to reach $986.3 million in 2017. If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at britni.myers@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country. AS is a chronic, inflammatory and genetically related disease that, being highly heritable, translates to a market with a stable patient population. Given that awareness is low, many cases go undiagnosed for years, signifying a much larger opportunity than previously estimated.